ANNUAL COSTS OF BEST SUPPORTIVE CARE FOR PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) IN GERMANY

被引：0
|
作者：
Mathes, J. [1 ]
Kern, B. [1 ]
Kotowa, W. [1 ]
机构：
[1] IGES Inst GmbH, Nurnberg, Germany
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.184
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN101
引用
收藏
页码：A430 / A430
页数：1
相关论文
共 50 条
  • [21] COST OF BEST SUPPORTIVE CARE FOR NON-SMALL CELL LUNG CANCER PATIENTS - A GERMAN PERSPECTIVE
    Schmidt, U.
    Lipp, R.
    Drechsler, M.
    VALUE IN HEALTH, 2014, 17 (07) : A629 - A629
  • [22] COMBINED CHEMOTHERAPY AND RADIOTHERAPY VERSUS BEST SUPPORTIVE CARE IN THE TREATMENT OF INOPERABLE NON-SMALL-CELL LUNG-CANCER
    LEUNG, WT
    SHIU, WCT
    PANG, JCK
    LAU, J
    TAO, M
    LEUNG, SF
    TEO, P
    ONCOLOGY, 1992, 49 (05) : 321 - 326
  • [23] Advanced Non-Small-Cell Lung Cancer
    Kwon, Hyun W.
    Ham, Soo-Youn
    Shin, Sang W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1997 - +
  • [24] PREDICTIVE FACTORS ASSOCIATED WITH GEFITINIB RESPONSE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Xu, F.
    Zhou, T.
    Duan, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 47 - 47
  • [25] Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
    Cappuzzo, F
    Bartolini, S
    Ceresoli, GL
    Tamberi, S
    Spreafico, A
    Lombardo, L
    Gregorc, V
    Toschi, L
    Calandri, C
    Villa, E
    Crinò, L
    BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 82 - 86
  • [26] Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer (NSCLC)
    Chen, Lian
    Chen, Rui
    Zhu, Zhe
    Zhang, Yichen
    Wen, Zhengwei
    Li, Yun
    Li, Xiaoming
    Luo, Yuwen
    Ma, Liyu
    Lin, Shuguang
    Chen, Xin
    CHINESE JOURNAL OF CANCER RESEARCH, 2014, 26 (04) : 466 - 470
  • [27] Retrospective analysis of a group of patients with advanced Non-Small-Cell lung cancer (NSCLC) treated with Gefitinib
    Bandera, M.
    Bascialla, L.
    Martinelli, B.
    Masera, G. L. Rodolfo
    Vallini, I.
    Zanlorenzi, L.
    Pinotti, G.
    ANNALS OF ONCOLOGY, 2005, 16 : 25 - 25
  • [28] INCIDENCE OF PERICARDIAL EFFUSION IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS RECEIVING IMMUNOTHERAPY
    Canale, M.
    Camerini, A.
    Lilli, A.
    Del Meglio, J.
    Huqi, A.
    Amoroso, D.
    Casolo, G.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0E) : E88 - E88
  • [29] A phase II study of oxaliplatin and docetaxel in patients with advanced non-small-cell lung cancer (NSCLC)
    Raez, L
    Santos, E
    Rocha-Lima, C
    Roman, E
    Kumar, P
    Farfan, N
    Decesare, T
    Lopes, G
    Rosado, M
    Wu, J
    LUNG CANCER, 2005, 49 : S265 - S265
  • [30] Bone Metastases and Efficacy of Immunotherapy in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Landi, L.
    D'Inca, F.
    Cortesi, E.
    Chiari, R.
    Grossi, F.
    Delmonte, A.
    De Marinis, F.
    Signorelli, D.
    Dazzi, C.
    Sperandi, F.
    Catino, A.
    Giannarelli, D.
    Parra, H. Soto
    Minuti, G.
    Bordi, P.
    Migliorino, M. R.
    Palla, A.
    Tonini, G.
    Cognetti, F.
    Santoro, A.
    Tassinari, D.
    Scoppola, A.
    Bidoli, P.
    Piantedosi, F.
    Maio, M.
    Crino, L.
    Cappuzzo, F.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S481 - S481
12345